Scarica l'app Stockscreener
25.22
3.36%
0.82
Precedente Chiudi:
$24.40
Aprire:
$24.6
Volume 24 ore:
20,071
Relative Volume:
0.70
Capitalizzazione di mercato:
$8.79B
Reddito:
$136.33M
Utile/perdita netta:
$-56.34M
Rapporto P/E:
-33.61
EPS:
-0.7504
Flusso di cassa netto:
$-18.87M
1 W Prestazione:
-4.76%
1M Prestazione:
-1.02%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$24.56
$25.28
Intervallo di 1 settimana:
$23.06
$26.05
Portata 52W:
$17.09
$26.55
Ascentage Pharma Group International Adr Stock (AAPG) Company Profile
Nome
Ascentage Pharma Group International Adr
Settore
Industria
Telefono
-
Indirizzo
-
Confronta AAPG con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AAPG
Ascentage Pharma Group International Adr
|
25.22 | 2.25B | 136.33M | -56.34M | -18.87M | -0.7504 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Ascentage Pharma Group International Adr Stock (AAPG) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-03-27 | Iniziato | JP Morgan | Overweight |
Ascentage Pharma Group International Adr Borsa (AAPG) Ultime notizie
Ascentage Pharma Unveils Promising Data on Alrizomadlin at ASCO 2025 - TipRanks
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors - GlobeNewswire Inc.
Ascentage Pharma Announces Successful AGM Resolutions on May 19, 2025 - TipRanks
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Clover Health Investments (CLOV), Xencor (XNCR) and Intellia Therapeutics (NTLA) - The Globe and Mail
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting By Investing.com - Investing.com South Africa
Ascentage Pharma Files Annual Report, Announces Shareholder Meeting - Investing.com
JPMorgan sets Ascentage Pharma stock to Overweight, $27 target - Investing.com
Takeda Pharmaceutical Company (TKPYY) Stock: Strategic Focus on Oncology and Growth Opportunities - Value the Markets
Ascentage Pharma to Announce 2024 Financial Results and Corporate Update - TipRanks
Avoid the Trap: 3 High-yield Dividend Stocks With Safe Payouts - The Globe and Mail
Ascentage Pharma IPO opens flat - Investing.com
Ascentage Pharma shares slide ahead of ADS debut on Nasdaq - Investing.com
Ascentage prices first biotech IPO of 2025, raising $126M - BioPharma Dive
Ascentage Pharma sets terms for $149 million US IPO - The Pharma Letter
Takeda-backed Ascentage Pharma files for $100M IPO (IPO:NYSEARCA) - Seeking Alpha
Market Capitalization: What It Is, Formula for Calculating It - Investopedia
Ascentage Pharma Announces Confidential Submission of Draft Registration Statement for Proposed Initial Public Offering of American Depositary Shares - PR Newswire
Takeda, Ascentage Pharma Sign Option Agreement - Contract Pharma
BIIB Stock Quote Price and Forecast - CNN
Capital Markets - Wilson Sonsini
Morningstar | Empowering Investor Success - Morningstar
ADVFN | Live Stock, Options & Crypto Market Data, Trading Tools & Community - ADVFN Logo
Ascentage Pharma Group International Adr Azioni (AAPG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
6.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):